Physiological and tumor-associated angiogenesis: Key factors and therapy targeting VEGF/VEGFR pathway - 08/11/24

Abstract |
Cancer remains one of the leading causes of death worldwide and poses a significant challenge to effective treatment due to its complexity. Angiogenesis, the formation of new blood vessels, is one of the cancer hallmarks and is a critical process in tumor growth and metastasis. The pivotal role of angiogenesis in cancer development has made antiangiogenic treatment a promising strategy for cancer therapy. To develop an effective therapy, it is essential to understand the basics of the physiological and tumor angiogenesis process. This review presents the primary factors related to physiological and tumor angiogenesis and the mechanisms of angiogenesis in tumors. We summarize potential molecular targets for cancer treatment by focusing on the vasculature, with the VEGF/VEGFR pathway being one of the most important and well-studied. Additionally, we present the advantages and limitations of currently used clinical protocols for cancer treatment targeting the VEGF/VEGFR pathway.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Angiogenesis is one of the cancer hallmarks and a critical process in tumor development. |
• | VEGF/VEGFR pathway signaling is crucial for normal and tumor-associated angiogenesis. |
• | Targeting the VEGF/VEGFR pathway offers promising potential for effective cancer therapy. |
• | Current angiogenesis targeting therapies have significant limitations, requiring new approaches. |
Keywords : Angiogenesis, Tumor-associated angiogenesis, VEGF, VEGFR, Cancer therapy, Hypoxia, Tumor microenvironment
Plan
Vol 180
Article 117585- novembre 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
